An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Summary

This is a Phase 1, open-label, multicenter, extension study. Subjects with non-Hodgkin's lymphoma (NHL) (excluding chronic lymphocytic lymphoma \[CLL\], small lymphocytic lymphoma \[SLL\], and mantle cell lymphoma \[MCL\]) who completed a prior ABT-199 study, or were active and assigned to ABT-199 when the study was completed, may roll over into this extension study. Subjects will receive ABT-199 during this study.

Timeline

Start

2013-12-20

Primary completion

2019-12-16

Completion

2019-12-16

Drugs

Indications